A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
Raynaud's phenomenon is thought to occur when, in response to cold or emotional stress, there
is closure of the digital arteries and cutaneous arterioles leading to the clinical finding
of sharp demarcated digital pallor and cyanosis of the distal skin of the fingers and/or
toes. Patients often continue to experience problems despite current available treatment. The
investigators' study will investigate the use of a new vasodilator called Fasudil, a
Rho-kinase inhibitor. The investigators' hypothesis is that Fasudil will prevent
vasoconstriction of digital and cutaneous arteries during a standard laboratory based cold
exposure and will therefore improve digital blood flow and skin temperature recovery time
following cold challenge. These data will provide the rationale for a more elaborate clinical
trials in real life situations.